What is the generic name of Zepbound (ozanimod)?

From the Guidelines

The generic name for Zepbound is ozanimod, as indicated in the provided evidence, specifically in the context of ulcerative colitis treatment. Zepbound, or ozanimod, is a medication that has been approved for the treatment of moderately to severely active ulcerative colitis in adults, as discussed in the studies 1. Ozanimod works as a sphingosine 1-phosphate receptor modulator, which helps in the treatment of ulcerative colitis by modulating the immune system. It is administered orally, once daily, with a dose of 0.92 mg, and has shown efficacy in inducing and maintaining clinical remission in patients with ulcerative colitis, as demonstrated in the True North trial 1.

• Key points about ozanimod include:
  • Its efficacy in treating moderately to severely active ulcerative colitis
  • Its safety profile, which includes a lower risk of certain adverse events compared to other therapies, such as thiopurines and biologics
  • Its convenience as an oral medication, which may improve patient adherence and quality of life
  • The importance of gradual dose escalation to mitigate cardiac events, such as bradycardia, as noted in the True North trial 1 While the provided evidence primarily discusses ozanimod in the context of ulcerative colitis treatment, it is essential to consider the medication's benefits and risks in the context of individual patient needs and medical history. As with any medication, careful consideration of the potential benefits and risks, as well as ongoing monitoring and patient education, are crucial for optimal treatment outcomes, as outlined in the guidance for ozanimod use 1.

From the FDA Drug Label

ZEPOSIA contains ozanimod, a sphingosine 1-phosphate receptor modulator The generic name of Zepbound is ozanimod 2

From the Research

Zepbound Generic Name

• The generic name for Zepbound is ozanimod, as mentioned in the studies 3, 4, 5, 6, 7.

Uses of Ozanimod

• Ozanimod is used to treat relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults 3.
• It is also used to treat moderately to severely active ulcerative colitis in adults 4, 6, 7.
• Ozanimod has been shown to be effective in inducing clinical remission and maintaining remission in patients with ulcerative colitis 6, 7.

Mechanism of Action

• Ozanimod is a sphingosine 1-phosphate (S1P) receptor modulator that binds with high affinity to S1P receptor subtypes 1 and 5 5.
• It has been shown to compete with other S1P receptor modulators for binding at the same site, suggesting that they can be considered interchangeable with one another 5.